INJ vs SUI: A Flow-Based Look at Derivatives Leverage and Price Action

The current speculative money flow for these two tokens tells a starkly different story. Injective (INJ) shows active leveraged trading, while Sui (SUI) reflects a deep, prolonged drawdown from its peak.

INJ is experiencing significant derivatives activity, indicating active leverage. The token's futures open interest sits at $51.70M with 24-hour futures volume reaching $73.50M. This volume is more than ten times its spot trading volume, highlighting a concentration of leveraged bets. Despite this active flow, the price is under pressure, down 4.66% over the past 24 hours. The token is also trading far from its highs, 94.4% below its all-time high of $52.62.

SUI's price action tells a different story of a market in a deep reset. The token is trading around $1.60–$1.70, which represents a roughly 70% decline from its January 2025 high near $5.35. This isn't a recent pullback but a sustained bearish move that has erased the majority of its value from its peak. The context suggests this is a high-beta infrastructure play now grappling with long-term vesting schedules and a high fully diluted valuation, which continues to weigh on sentiment.

Catalysts and Supply Dynamics

The forward path for SUI hinges on a supply shock and institutional catalysts. Analysts project a potential price range of $2.20–$4.10 if spot ETFs are approved by mid-2026, a scenario that would inject significant new demand. This institutional validation is already underway, with a live leveraged ETF and a Grayscale trust filing, creating a structural channel for capital.

Structurally, SUI faces a major overhang. The token has a fixed supply of 10 billion tokens, with roughly 3.7 billion in circulation as of late 2025. This leaves a fully diluted valuation exceeding $16 billion, a massive supply overhang that continues to cap sentiment. The primary risk is that this large, fixed supply and its associated unlock schedule will pressure the price, even as the chain's performance and institutional interest grow.

The setup is a classic tension between utility and tokenomics. SUI's technical execution is elite, and the path to regulated ETFs is clear. Yet the sheer scale of its potential supply-over 60% of the total token count still unvested-creates a persistent ceiling. Any ETF-driven rally will need to overcome this fundamental supply pressure.

What to Watch

The current flow narrative for both tokens hinges on a few critical data points and catalysts. For Injective, the key is whether the high level of leveraged futures activity can support a sustained price recovery above its current level.

The token's futures open interest sits at $51.70M with 24-hour volume of $73.50M, indicating active speculation. The critical test is whether this leverage can reverse the recent 4.66% daily decline and push price above the $2.74 resistance level. A breakout would signal the leverage is fueling a genuine recovery, while failure would confirm the price remains under pressure from broader market sentiment.

For Sui, the primary watchpoint is its performance through its token unlock schedule. The market has already shown resilience, absorbing a $60 million token unlock on January 1 with notable price stability. Monitoring subsequent unlocks will reveal if this stability holds or if the large, fixed supply continues to act as a persistent overhang.

A broader catalyst to watch is regulatory progress on U.S. spot crypto ETFs. As noted in the outlook, clearer global frameworks will continue to change how institutions approach strategy. Approval for SUI ETFs, in particular, could act as a powerful structural catalyst, injecting new demand and validating the token's institutional case. For both tokens, the path forward will be defined by these specific flows, unlocks, and regulatory milestones.